ISO 9001:2008 Certification
IsoSciences is a world leader in stable isotope labeling of biological molecules, APIs and other custom synthesized molecules. In a ongoing effort to improve the rigorous manufacturing protocols of our molecules, IsoSciences has as now been certified to the ISO 9001:2000 standard of quality.
For well over a decade IsoSciences has been synthesizing stable isotope labeled molecules and has now been formally recognized by the International Organization of Standardization (ISO), audited by internationally renowned BSI.
ISO 9001 is the most comprehensive level of certification, accepted by 90 countries around the world. It provides third-party assurance that we have the quality management to ensure all software components, which we author are consistently of the highest quality.
Verification of the full ISO 9001:2008 certificate can be found here.
IsoSciences continues to set the industry standard for quality and innovation with new stable isotope labeled molecules that are manufactured and handled in facilities that are certified for good manufacturing practices (cGMPs) and good laboratory practices (GLP). Our clients' needs for production of APIs and molecules of biological interest has been answered with our introduction of cGMP techniques and documentation.
Vitamin D Standards - New Chemistry
Stable isotope labeled Vitamin D standards were pioneered by IsoSciences. Current derivatives that are available include the active Vitamin D3 metabolite 25-Hydroxyvitamin D3-[2H3] (cholicalciferol-d3; CAS 140710-94-7), with deuterium at the preferred 6,19,19 positions. The strategic location of deuterium atoms allows deuterium to be retained in the daughter ions of the compound, allowing a improved diagnostic analysis.
The patent pending methodology employed by IsoSciences is used to prepare all the Vitamin D compounds, yielding high incorporation of deuterium. Additionally, the preparations minimize or eliminate the presence of any unlabeled compound that would otherwise interfere with your mass spectroscopic assay.
All other vitamins synthesized by IsoSciences catalog can be found here.
(Trevose, PA) July30, 2012 - Global Healthcare Partners LLC (“GHP”) and Addison Capital Partners (“ACP”), in partnership with the existing management team, are pleased to announce the completion of the recapitalization of MPD Chemicals (“MPD” or the “Company”).
Based in Trevose, PA, MPD manufactures specialty chemicals with expertise in multiple technical areas including complex organic synthesis, unique monomers, polymer development, organosilicone chemistries and stable isotope labeling, which are primarily used in the manufacture of medical devices, industrial materials, pharmaceuticals and other niche applications.The Company is comprised of three distinct business units: Monomer-Polymer and Dajac Labs, Silar Laboratories and IsoSciences. MPD has three R&D and production facilities in Trevose, PA, King of Prussia, PA and Scotia, NY, coupled with ISO 9001 scale up lab and main reactor campus near Wilmington, NC.
With the recapitalization and new investor base consisting of industry and private equity executives, MPD plans to accelerate sales growthpenetration using the group’s collective and extensive relationships, network and expertise in the Company’s existing end markets and customer base. MPD will also look to expand into additional chemistry and technical arenas creating a fully integrated provider of solutions for a number of key and growing markets.
“MPD has built a reputation as a leading, fully integrated, critical supplier of final, complex and often novel materials.” said GHP Principal Doug Rogers. “GHP and ACP principalsare excited to partner with Dr. Bell and his team and are committed to enhancing shareholder value and supporting MPD’s next phase of growth.”
“Continuing MPD’s exceptional growth is dependent on finding the right partners in both end application clients and its investor base. The management at MPD is delighted to add GHP as partners and relishes the opportunities they bring to our organization. We all look forward to many more years extending the current growth of MPD Chemicals.” added Stephen Bell, CEO.
About MPD Chemicals:
MPD Chemicals is a US based manufacturerof specialty chemicals with expertise in multiple technical areas including complex organic synthesis, unique monomers, polymer development, organosilicone chemistries and stable isotope labeling. The Company is comprised of three distinct manufacturing units: Monomer-Polymer and Dajac Labs, Silar Laboratories, and IsoSciences. MPD services a variety of industrial and commercial markets including medical devices (e.g. ophthalmic lenses, wound care applications, implantable device coatings and dental resins), pharmaceuticals, adhesives and various industrial materials.
With a dedicated team of 63 employees (17 with advanced degrees, including 10 Ph.D. chemists) in R&D, engineering, quality assurance and manufacturing, MPD collaborates with its customers’ to develop novel materials for customer application needs by leveraging cross-disciplinary expertise with operational strength in scaling from milligram to metric ton batches.
MPD is headquartered in Trevose, Pennsylvania and operates three R&D and production facilities in PA and NY, coupled with an ISO-9001:2008 certified scale up lab and main reactor campus near Wilmington, North Carolina.For more information, please visit us at www.mpdchemicals.com.
About Global Healthcare Partners LLC:
GHP is a group of healthcare industry and private equity executives that investing the lower middle-market. The group typically invests between $10 million and $50 million in equity to sponsor buyouts, growth initiatives, corporate spin-offs and recapitalizations in the health care sector.The group has been investing together and through predecessor groups for over 25 years and has a preeminent track record in health care buyouts.
About Addison Capital Partners:
ACP is a private equity investment firm that seeks out partnerships with owners and operators of “smaller” middle market growth companies to provide liquidity, growth capital and management resources to grow and build exceptional enterprises.ACP looks to create true partnerships with exceptional businesses typically in value-added distribution, with manufacturer/distributors or niche manufacturing and business service companies. For more information, please visit us at www.addisoncapitalpartners.com.
King of Prussia, PA – June 29th, 2012
As part of the recent corporate transition, IsoSciences is proud to unveil their new website today for immediate use. As one may have already noticed, quite a few things have changed.
While users will notice the transformation in design, IsoSciences hopes that our website visitors will take advantage of the more functional aspects that have been added. Specifically, users are able to register, allowing them access to a complete online purchasing method, bulk quote submissions, downloads of MSDS, certificates of analysis and full product lists. For ease of use, a search function is available on every page and can be completed using full and partial product names, product ID and CAS numbers.
The overall navigation hasn't changed significantly, with the same broad categories of compounds available, including vitamins, steroids, Certimass and other labeled molecules of interest. Some additional informational pages, MSDS, certificates of analysis, molecular structures, key physical property information and bulk quote requests have also been added to improve the technical information available to users.
Trevose, PA – December 2nd, 2011
Monomer-Polymer and Dajac Labs announced today that it has acquired IsoSciences, LLC.
Monomer-Polymer and Dajac Labs today announced it has completed the acquisition of IsoSciences, LLC, a privately-held manufacturer of stable isotope-labeled hormones, vitamins and specialty organic chemicals, located in King of Prussia, Pennsylvania. IsoSciences will become a subsidiary of the parent MPD Holdings and will complement MPD's existing portfolio of specialty and performance chemicals.
Research and development of novel materials for demanding industries is the core of MPD's success and growth over the last 35 years. The recent integration of Monomer-Polymer and Silar has garnered many recent successes for MPD, creating solutions for technically challenging projects in the biomedical device, dental, wound care, and electronics industries. The success of this interdisciplinary research is based not only the ability to create new molecules, but also on gaining a fundamental understanding of the underlying mechanisms and modes of action. With the addition of IsoSciences, MPD will have the ability to create molecules with easily detected markers, allowing MPD to create additional solutions using stable isotope labeled materials.
Monomer-Polymer and Dajac Labs has undertaken specialty monomer and polymer research for over 50 years, creating an extensive datacenter of highly technical monomers and related polymers and copolymers. MPD specialties include acrylates, methacrylates, fluorinated molecules, silanes and vinyl monomers, in addition to the corresponding polymers and copolymers. MPD's specialty monomers and polymers are broadly used, serving many markets including coatings, adhesives, medical devices, dental resins, wound care, academic and industrial R&D.
IsoSciences is a world leader in providing custom synthesized isotope labeled compounds including intermediates, final drug substances, and isotopically labeled biological standards. Molecule development is undertaken with a focus on servicing pharmaceutical companies and other research organizations that require isotopically labeled compounds and other non-labeled organic intermediates as well as metabolites. The Company's chemists have more than 100 years' combined experience preparing isotopically labeled compounds and non-labeled organic intermediates and metabolites.
"Incorporation of stable isotope labels into our current specialty chemicals offers many exciting opportunities for the development of materials utilizing knowledge of underlying mechanisms. IsoScience's experienced management and diverse technical teams in collaboration with the organosilane and specialty monomer business units will allow MPD to further diversify its technical offering by creating unique stable isotope labeled materials and production of pharmaceutical precursors and intermediates," said Stephen Bell, CEO of MPD. "We are excited to have IsoSciences join our organization and look forward to developing these opportunities with them."
Scott Landvatter, CEO of Isosciences said, "Joining forces with a high quality specialty chemical producer like MPD offers IsoSciences the greatest potential for growing our business, expanding our capabilities and maximizing value for our customers."